Milestone Pharmaceuticals Inc. (MIST) - 10-Q Summary
Business Context and Reporting Period
Company: Milestone Pharmaceuticals Inc.
Reporting Period: Quarter ended June 30, 2025 (Q2 2025)
Business Focus: Biopharmaceutical company developing cardiovascular medicines, primarily focused on etripamil (CARDAMYST), a rapid-onset nasal spray for paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR).
Regulatory Status: Received a Complete Response Letter (CRL) from the FDA in March 2025 regarding the PSVT New Drug Application (NDA). The company submitted a response on June 13, 2025, which was accepted by the FDA on July 11, 2025, setting a new PDUFA target date of December 13, 2025.
Key Financial Metrics
| Metric (in thousands USD) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(12,966) | $(9,363) | $(33,727) | $(19,717) |
| Loss Per Share (Basic/Diluted) | $(0.20) | $(0.14) | $(0.51) | $(0.34) |
| Operating Expenses | $12,531 | $9,662 | $33,054 | $20,138 |
| Cash & Cash Equivalents (End of Period) | $42,499 | $13,262 | $42,499 | $13,262 |
| Short-term Investments | $918 | $44,381 | $918 | $44,381 |
| Total Liquidity (Cash + ST Inv) | $43,417 | $57,643 | $43,417 | $57,643 |
| Senior Secured Convertible Notes | $55,238 | $53,352 | $55,238 | $53,352 |
| Accumulated Deficit | $(401,272) | $(345,743) | $(401,272) | $(345,743) |
Material Changes vs. Prior Period
- Commercial Expenses Surge: Commercial expenses increased by 183.3% in Q2 2025 ($5.1M vs $1.8M) and 230.4% for the six months ($15.5M vs $4.7M) due to preparations for the potential launch of CARDAMYST. However, the company temporarily paused the ramp-up of launch expenditures following the March 2025 CRL.
- R&D Expenses: Increased 30.3% in Q2 2025 ($3.7M vs $2.8M) driven by higher consulting and outside service costs, partially offset by lower personnel costs.
- Liquidity Shift: While cash and cash equivalents increased to $42.5M (from $25.3M at year-end 2024), total liquidity decreased compared to the prior year due to the redemption of $44.5M in short-term investments during the six months ended June 30, 2025.
- Net Loss Expansion: Net loss widened by 38.5% in Q2 and 71.1% for the six months compared to the prior year periods, reflecting increased operational spending.
Guidance, Outlook, and Risks
- Regulatory Outlook: The FDA accepted the company's response to the CRL on July 11, 2025, with a new decision date of December 13, 2025. The CRL cited Chemistry, Manufacturing, and Controls (CMC) issues regarding nitrosamine impurities and a required facility inspection.
- Capital Resources: Management expects existing cash, short-term investments, and proceeds from a subsequent equity offering (see below) to fund operations for at least the next 12 months.
- Subsequent Equity Offering: On July 11, 2025, the company completed an underwritten public offering of common shares and warrants, raising approximately $48.7 million in net proceeds.
- Royalty Agreement Amendment: On July 10, 2025, the company amended its Royalty Purchase Agreement with RTW Investments, extending the marketing approval deadline for etripamil from September 30, 2025, to December 31, 2025.
- Risks: Primary risks include the uncertainty of FDA approval despite the CRL response, the need for additional financing if approval is delayed, and potential impacts from international trade policies on supply chains (APIs sourced from China).
Key Facts for Investor Verification
- Approval Timeline: Verify the status of the FDA review following the July 11, 2025 acceptance of the CRL response and the December 13, 2025 PDUFA date.
- Cash Burn Rate: Monitor the impact of the $48.7M July 2025 capital raise on the company's runway, given the $26.5M cash burn from operations in the first six months of 2025.
- Commercial Spend: Assess whether commercial expenses will remain elevated or be further curtailed pending the FDA decision.
- Debt Obligations: Review the terms of the $55.2M Senior Secured Convertible Notes due 2029, including interest expense and potential conversion triggers.
- Supply Chain: Confirm the resolution of the CMC inspection issues and the stability of the supply chain for active pharmaceutical ingredients (APIs) sourced from China amidst trade tensions.